Influence of abiraterone acetate on neuroendocrine differentiation in chemotherapy-naive metastatic castration-resistant prostate cancer
Influence of abiraterone acetate on neuroendocrine differentiation in chemotherapy-naive metastatic castration-resistant prostate cancer
复制标题
醋酸阿比特龙对初治转移性去势抵抗性前列腺癌神经内分泌分化的影响
DOI：
10.1002/pros.23397
复制
发表时间：
2017-09-15
期刊：
影响因子：
2.8
通讯作者：
Xue, Wei
中科院分区：
文献类型：
--
作者：
Dong, Baijun;Fan, Liancheng;Xue, Wei
BackgroundTo determine the influence of abirterone Acetate（AA）on neuroendocrine differentiation（NED）in patients with chemotherapy-naive metastatic castration-resistant prostate cancer（mCRPC）.MethodsWe conducted an analysis in 115 chemotherapy-naive mCRPC patients who would be treated with chemotherapy.检测67例未经AA治疗的mCRPC患者和48例AA治疗失败的mCRPC患者血清嗜铬粒蛋白A（CgA）、神经元特异性烯醇化酶（NSE）水平，其中34例患者在AA治疗前和治疗6个月后检测上述指标。结果化疗前血清CgA和NSE高于正常上限（ULN）者分别为56例（48.7%）和29例（25.2%）;在连续评估的34例患者中，14例患者在AA治疗失败后血清CgA水平升高，14例患者NSE升高。治疗前与治疗失败后NED标志物（CgA、NSE）变化差异无统计学意义（P=0.243）。与AA治疗前6个月CgA升高组和基线CgA超常组相比，CgA下降组和基线CgA正常组的中位PSA PFS更长（14.34 vs 10.00个月，P
BackgroundTo determine the influence of abiraterone Acetate (AA) on neuroendocrine differentiation (NED) in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC).MethodsWe conducted an analysis in 115 chemotherapy-naive mCRPC patients who would be treated with chemotherapy. The serum levels of chromogranin A (CgA), neurone-specific enolase (NSE) were measured in 67 mCRPC patients without AA treatment and 48 patients after the failure of AA treatment, in which these markers were also measured in 34 patients before and after 6 months of AA treatment. Comparative t-test was used to evaluate the serial changes of serum NED markers during AA treatment and univariate and multivariate analyses were performed to test the influence of AA treatment on NED.ResultsSerum CgA were NSE were evaluated to be above the upper limit of normal (ULN) in 56 (48.7%) and 29 (25.2%) patients before chemotherapy. In 34 patients with serial evaluation, serum CgA level of 14 patients and NSE of 14 patients increased after the failure of AA treatment. There was no significant difference of NED markers (CgA or NSE variation (P=0.243) between at baseline and after the failure of AA treatment. Compared with the CgA elevation group in the first 6 months of AA treatment and baseline supranormal CgA group, the CgA decline group, and baseline normal CgA group has a much longer median PSA PFS (14.34 vs 10.00 months, P